(MENAFN- GetNews) The Key Prader-Willi Syndrome Companies in the market include - Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, ...

CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a ...

(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...

US biotechs Acadia Pharma and Harmony Biosciences have both suffered setbacks in phase 3 trials of drugs for rare diseases – respectively Prader-Willi and Fragile X syndrome, and in one case at least, ...

Soleno Therapeutics (SLNO) has been initiated with Buy at Goldman Sachs citing strong fundamentals and blockbuster potential for its lead asset, Vykat XR, in treating Prader-Willi syndrome. After ...

Imprinting is epigenetic marking of a locus on the basis of its parental origin, which can result in differential expression of the paternal and maternal alleles in specific tissues or developmental ...